January 25, 2010 (FinancialWire) — Curis, Inc. (NASDAQ: CRIS) said it has priced a registered direct offering of 6,449,288 units, at a price of $2.52 per unit, for gross proceeds of $16.25 million.

Each unit consists of one share of the company’s common stock and a warrant to buy 0.25 of a share of the company’s common stock. The warrants will be exercisable for a period of five years beginning on the date of issuance, at an exercise price of $3.55 per share.

The closing of the offering is scheduled to take place on or about January 27, 2010.

Curis plans to use the net proceeds of the offering for general corporate purposes, including but not limited to conducting further preclinical testing and clinical studies of its product candidates, including CUDC-101, and its other proprietary targeted cancer small molecule compounds; for capital expenditures; and working capital.

Massachusetts-based Curis is a drug development company that is expanding its focus on a targeted cancer drug development platform.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.